文献速递青光眼

多族裔亚洲人群中全身用药与眼压的关联:新加坡眼病流行病学研究

Association of Systemic Medication Use With Intraocular Pressure in a Multiethnic Asian Population: The Singapore Epidemiology of Eye Diseases Study.
PubMed 文献 · JAMA Ophthalmol · 2017-01-01

该研究为新加坡眼病流行病学研究的回顾性分析,纳入8063名多族裔亚洲参与者,评估全身用药与眼压的关联。结果显示全身β受体阻滞剂使用与眼压降低0.45毫米汞柱独立相关,而血管紧张素转换酶抑制剂、血管紧张素受体阻滞剂、他汀类和磺脲类药物使用与眼压升高相关,但关联幅度较小。

要点

  • 全身β受体阻滞剂使用与眼压降低0.45毫米汞柱独立相关(95%CI -0.65至-0.25毫米汞柱,P<.001)。
  • 血管紧张素转换酶抑制剂、血管紧张素受体阻滞剂、他汀类和磺脲类药物使用与眼压升高相关,幅度在0.21至0.40毫米汞柱之间。
  • 仅全身降糖药与眼压的关联超过1毫米汞柱,其他研究中该阈值对应5年内青光眼风险增加14%。

核心结论

  • 全身β受体阻滞剂使用与较低眼压相关,而血管紧张素转换酶抑制剂、血管紧张素受体阻滞剂、他汀类和磺脲类药物使用与较高眼压相关,但关联幅度最多为中等。
  • 仅全身降糖药与眼压的关联超过1毫米汞柱,在其他研究中该阈值对应5年内青光眼风险增加14%。
  • 全身用药对青光眼患眼眼压的影响尚未充分阐明但很重要;青光眼患者可能因药物类别不同而面临眼压升高或降低的风险,进而影响眼压控制管理。

研究设计与样本

  • 新加坡眼病流行病学研究的回顾性分析,基于人群研究,初始纳入10033名参与者(应答率78.7%),来自3个种族/族裔群体:华人(招募时间2009年2月9日至2011年12月19日)、马来人(招募时间2004年8月16日至2006年7月10日)和印度人(招募时间2007年5月21日至2009年12月29日)。
  • 排除青光眼、既往眼部手术或外伤以及双眼眼压不对称大于5毫米汞柱的参与者后,最终分析8063人(平均[标准差]年龄57.0[9.6]岁;女性4107人[50.9%];华人2680人[33.2%]、马来人2757人[34.2%]、印度人2626人[32.6%])。
  • 眼压采用Goldmann压平眼压计测量;通过访谈者 administered 问卷收集药物及其他变量数据;数据分析时间为2015年8月1日至10月31日。
  • 采用线性回归模型评估药物与眼压的关联,调整年龄、性别、体重指数、族裔及用药对应的医疗状况(血管紧张素转换酶抑制剂、血管紧张素受体阻滞剂和β受体阻滞剂调整血压,他汀类调整血脂,双胍类、磺脲类、α-糖苷酶抑制剂和胰岛素调整糖化血红蛋白);将显著关联眼压差异的药物纳入调整多种药物 concomitant 使用的回归模型;使用广义估计方程模型考虑双眼相关性。

主要发现

  • 全身β受体阻滞剂使用与眼压降低0.45毫米汞柱独立相关(95%CI -0.65至-0.25毫米汞柱;P<.001)。
  • 血管紧张素转换酶抑制剂使用与眼压升高0.33毫米汞柱相关(95%CI 0.08至0.57毫米汞柱;P=.008)。
  • 血管紧张素受体阻滞剂使用与眼压升高0.40毫米汞柱相关(95%CI 0.40至0.75毫米汞柱;P=.02)。
  • 他汀类药物使用与眼压升高0.21毫米汞柱相关(95%CI 0.02至0.4毫米汞柱;P=.03)。
  • 磺脲类药物使用与眼压升高0.34毫米汞柱相关(95%CI 0.05至0.63毫米汞柱;P=.02);未发现药物类别间对眼压的相加、协同或拮抗效应交互作用。

关键数值与推荐

  • 全身β受体阻滞剂使用与眼压降低0.45毫米汞柱独立相关(95%CI -0.65至-0.25毫米汞柱;P<.001)。
  • 血管紧张素转换酶抑制剂使用与眼压升高0.33毫米汞柱相关(95%CI 0.08至0.57毫米汞柱;P=.008)。
  • 血管紧张素受体阻滞剂使用与眼压升高0.40毫米汞柱相关(95%CI 0.40至0.75毫米汞柱;P=.02)。
  • 他汀类药物使用与眼压升高0.21毫米汞柱相关(95%CI 0.02至0.4毫米汞柱;P=.03)。
  • 磺脲类药物使用与眼压升高0.34毫米汞柱相关(95%CI 0.05至0.63毫米汞柱;P=.02)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: There is limited understanding of the associations between systemic medication use and intraocular pressure (IOP) in the general population. OBJECTIVE: To examine the association between systemic medication use and IOP in a multiethnic Asian population. DESIGN, SETTING, AND PARTICIPANTS: In this post hoc analysis of the Singapore Epidemiology of Eye Diseases study, a population-based study of 10 033 participants (78.7% response rate) from 3 racial/ethnic groups (Chinese [recruited from February 9, 2009, through December 19, 2011], Malays [recruited from August 16, 2004, though July 10, 2006], and Indians [recruited from May 21, 2007, through December 29, 2009]), participants with glaucoma, previous ocular surgery, or trauma and an IOP asymmetry greater than 5 mm Hg between eyes were excluded. Intraocular pressure was measured using Goldmann applanation tonometry. An interviewer-administered questionnaire was conducted to collect data on medication and other variables. Data analysis was performed from August 1 through October 31, 2015. MAIN OUTCOMES AND MEASURES: Associations between medication and IOP were assessed using linear regression models adjusted for age, sex, body mass index, ethnicity, and the medical condition for which the medication was taken (angiotensin-converting enzyme inhibitors [ACEIs], angiotensin receptor blockers [ARBs], and β-blockers adjusted for blood pressure, statins adjusted for lipids, and biguanides, sulfonylureas, α-glycosidase inhibitors [AGIs], and insulin adjusted for glycosylated hemoglobin). Medications associated with significant IOP differences were incorporated into regression models adjusted for concomitant use of multiple medications. Generalized estimating equation models were used to account for correlation between eyes. RESULTS: Of the 10 033 participants, we analyzed 8063 (mean [SD] age, 57.0 [9.6] years; 4107 female [50.9%]; 2680 Chinese [33.2%], 2757 Malay [34.2%], and 2626 Indian [32.6%] individuals). Systemic β-blocker use was independently associated with an IOP of 0.45 mm Hg lower (95% CI, -0.65 to -0.25 mm Hg; P < .001). Conversely, higher mean IOP was associated with use of ACEIs (0.33 mm Hg higher; 95% CI, 0.08 to 0.57 mm Hg; P = .008), ARBs (0.40 mm Hg higher; 95% CI, 0.40-0.75 mm Hg; P = .02), statins (0.21 mm Hg higher; 95% CI, 0.02-0.4 mm Hg; P = .03), and sulfonylureas (0.34 mm Hg higher; 95% CI, 0.05-0.63 mm Hg; P = .02). An interaction between medication classes for additive, synergistic, or antagonistic effects on IOP was not identified. CONCLUSIONS AND RELEVANCE: Although systemic β-blocker use was associated with lower IOP and systemic ACEI, ARB, statin, and sulfonylurea use was associated with higher IOP in this study, the associations were modest at best. Only the associations with systemic hypoglycemic agents were greater than 1 mm Hg, a threshold that has translated to a 14% greater risk of incident glaucoma across 5 years in other studies. At this point, the effect of systemic medication on IOP in eyes with glaucoma is not well elucidated but important. Our findings indicate that patients with glaucoma may potentially be at risk of higher or lower IOP, depending on medication class, and this would in turn affect management of IOP control.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Ho H, Shi Y, Chua J, et al. Association of Systemic Medication Use With Intraocular Pressure in a Multiethnic Asian Population: The Singapore Epidemiology of Eye Diseases Study. JAMA Ophthalmol. 2017. PMID: 28097295. doi:10.1001/jamaophthalmol.2016.5318

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。